Clinica Montecanal S.L.
- Address
- Calle Franz Schubert 2, 50012 Zaragoza, Spain
Clinica Montecanal S.L. - Neurodegenerative Disease Research Center
Clinica Montecanal S.L. is a distinguished clinical research center specializing in neurodegenerative disorders, with a primary focus on Alzheimer's disease and Parkinson's disease. The center demonstrates exceptional expertise in conducting complex Phase 2 and Phase 3 trials, evaluating novel therapeutic approaches including monoclonal antibodies, active immunotherapies, and innovative pharmacological interventions targeting disease-modifying pathways.
- Alzheimer's disease across all stages: preclinical, mild cognitive impairment (MCI), and mild dementia, with extensive experience in cognitive and functional assessment scales
- Neuropsychiatric complications of Alzheimer's disease, including psychosis and agitation management trials
- Early Parkinson's disease progression studies evaluating motor and non-motor outcomes
- Advanced immunotherapy trials targeting amyloid-beta and phosphorylated tau proteins
The center has established comprehensive capabilities in conducting long-term extension studies and open-label evaluations, demonstrating commitment to understanding sustained treatment effects and safety profiles. Their research portfolio includes investigations of cutting-edge therapeutic mechanisms such as muscarinic receptor modulation, tau-targeted active immunization, and alpha-synuclein targeting strategies. With expertise in utilizing standardized assessment tools including CDR-SB, iADRS, CMAI, and BEHAVE-AD scales, Clinica Montecanal S.L. provides robust clinical data supporting the development of transformative treatments for patients suffering from progressive neurodegenerative conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinica Montecanal S.L.
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of ITI-1284 in Psychosis Associated with Alzheimer's Disease: A Randomized, Double-Blind, Placebo-Controlled Study | Intra-Cellular Therapies Inc. | Phase II | Recruiting | Jul 2025 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Trospium Chloride | 4 | Unknown | 2024-05-09 | 2026-06-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.